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It is necessary that an adequate microbiology capability be provided
as part of the Health Maintenance Facility (HMF)to support expected
microbial disease events during long periods of space flight. The
applications of morphological and biochemical studies to confirm the
presence of certain bacterial and fungal disease agents are currently
available and under consideration. This confirmation would be greatly
facilitated through employment of serological methods to aid in the
identification for not only bacterial and fungal agents, but viruses as
well. A number of serological approaches were considered, particularly
the use of Enzyme-Linked IrmmmosorbentAssays (ELISAs), which could be
utilized during space flight conditions.
A solid phase, membrane supported ELISA for the detection of
Bordetella pertussis was developed to show a potential model system
that would meet the HMF requirements and specifications for the future
space station. A second model system for the detection of Legionella
pneumophila, an expected bacterial disease agent, is currently under
investigation. These preliminary studies demonstrate the capability
of ELISA systems for identification of expected microbial disease
agents as part of the HMF.
NASA Colleague: Duane L. Pierson, Ph.D. SD4 X5457
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INTRODUCTION
The health and well being of individuals aboard a space station and
possibly during future long space missions is of priority and must be
assured. Certain expected clinical syndromes and diseases have been
identified through an infectious disese conference conducted during
October, 1985. Previous spaceflight studies indicate a high probability
of cross-contamination among crewmembers during long confinements, such
as the 90 day missions planned for the space station (12). Continual
habitation, crowded conditions, possible immunosuppression, and other
factors may create critical situations aboard the space craft. If a
microbial disease is suspected, the major effort would be directed
toward obtaining some indication of the specific kind of microorganism
causing the problem. The exact nature of the etiologic agent would
determine the severity of the disease, treatment, prophylaxis, and
subsequent health measures for the space station environment.
The diagnosis of a microbial disease rests upon one or a combin-
ation of clinical signs and symptoms, morphological and biochemical
identification of isolates, and/or serological procedures. Special
procedures such as cell culture may also be required. One problem with
limiting the scope of diagnosis to clinical signs and symptoms is that
a particular microbe can sometimes produce infection having very
different clinical characteristics and occuring in widely different
areas of the body. For example, antibiotic-resistant Staphylococcus
aureus may produce skin and subcutaneous tissue lesions as well as
pneumonia, osteomyelitis, bacteremia, and acute membranous entercolitis,
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depending upon the means by which the organism gained entrance to the
body, host resistance, antibiotic therapy, and other factors.
While the principle of one microorganism causing one clinical
disease is often valid, there are many situations where this is not
true. Indeed, pneumonias that are hardly separable clinically may be
produced by several different kinds of bacteria and viruses. Correct
diagnosis and treatment therefore heavily depend upon the abilities of
the clinical laboratory.
It is important to note that serological procedures will not
immediately take the place of needed morphological and biochemical
identification of bacteria or fungi; however, they are frequently used
to verify, compare, and further substantiate those results as well as
provide a means to directly identify viruses or the immunological
response to a viral infection.
Over the past few years, many new i_munological methods have been
developed which now provide the clinical laboratory with a large array
of potentially valuable diagnostic tools. Antibodies and antigens
labeled with radioisotopes or fluorescent dyes, or affixed to parti-
culate materials, have been used extensively for immunodiagnosis over
the past three decades. These methods do have disadvantages. Immuno-
fluorescence, for example, usually depends upon a subjective assessment
of end result, and the technique is frequently laborious. Radioi_muno-
assay requires expensive equipment and carries the risk of radioactive
exposure and contamination.
The concepts that antigen and antibody can be attached to a solid
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phase support yet retain immunological activity, and that either can
be coupled to an enzyme and the complex retain both immunological and
enzymatic activity, led to the development of Enzyme-Linked Immuno-
sorbent Assays (ELISAs). Antibodies and antigens have been shown to
readily attach to plastic surfaces (such as polyvinyl or polystyrene)
either by passive absorption or chemical conjugation, and still retain
immunological activity. Antibodies and antigens have been linked to
a variety of enzymes including glucose oxidase, peroxidase, and
alkaline phosphatase. The positive factors for ELISAs include low
cost, reagent stability, safety, sensitivity, reproducibility, and
ease of procedure. The procedures are simple enough to be performed
in even poorly equipped laboratories.
It appears likely that the space station diagnostic capability
will require inmlunological testing applicable to the identification of
microorganisms, particularly viruses. In recent years, there has been
increasing emphasis on accurate, reliable, and quick immunological
®
procedures for the identification of many microorganisms and/or the
immunological responses of the host toward infection. Most current
procedures have been developed for use in clinical labortories and
not designed for a space station environment. It appears and is
reasonable that a number of some exsisting procedures, particularly
solid phase immunoassays, could be modified in regard to uniformity
and standardization for use aboard the space station. This project
was designed to illustrate the concept of a solid phase, membrane
supported ELISA to demonstrate the capability of ELISA systems for
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identification of expected microbial disease agents aboard the space
station.
The main purpose of this project was to assess the current ELISA
technological trends and procedures in the immunological identification
of viral and bacterial diseases, particularly those microorganisms
expected to cause illness aboard a space station, and to determine
which procedures could be effectively implemented into the space
station microbiology diagnostic capability as part of the HMF (Health
Maintenance Facility).
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MATERIALS
Equipment. A 96 well Bio-Dot filtration apparatus (#170-6550) was
obtained from Bio-Rad Laboratories, Richmond, Ca. 94801.
Buffers. A 20 mM Tris buffered saline (TBS), pH 7.5, was prepared
by adding 4.84 g Tris (Bio-Rad) to 58.48 g NaCl, brought to a 2.0 1
volume with deionized water. The buffer was adjusted to pH 7.5 with
HCl.
Blocking Solution. A 3.0% BSA-TBS solution was prepared by adding
3.0 g of bovine serum albumin (Difco) to i00 ml of TBS.
Wash Solution. A wash solution containing 0.05% Tween-20 was
prepared by adding 0.5 ml of Tween-20 (Bio-Rad) to 1 1 of TBS.
Antibodies. A human serum pool containing antibodies to Borde-
tella pertussis was obtained from the clinical laboratories at NASA,
Johnson Space Center. Antiserum to Legionella pneumophila (serogroup
i) was obtained from Dr. Hazel Wilkinson, the Department of Health and
Human Services, Center for Disease Control, Atlanta, Ga. 30333.
Horseradish peroxidase conjugated (HPR) goat anti-rabbit (#170-6500)
and (HPR) goat anti-human (#172-1050) were obtained from Bio-Rad
Laboratories.
Antigens. Bordetella pertussis antigen (#2515) was obtained from
Difco Laboratories, Detroit, Mi. 48232. This concentration of this
preparation was 2 x McFarlands units (equivalent to approximately
9
1.8 x i0 organisms/ml). Legionella pneumophila antigen was prepared
from a ATCC 3152 (serogroup i) lyophilized culture vial (13). The
ATCC vial was broken and the lyophilized material was dissolved into
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4 ml of Trypticase Soy Broth. Four 15 x i00 mm plates containing 25 ml
of buffered charcoal yeast extract (BCYE) agar was each inoculated with
1.0 ml of the dissolved material. The plates were enclosed.in a plastic
container to prevent the agar from drying out and were incubated at
o
35 C for 48 hr. The cells were suspended from each agar surface in 3.0
ml of sterile 0.01 M phosphate buffered saline, pH 7.2, with a pasteur
pipette into a 25 ml sterile conical tube. The conical tube containing
the cell suspension was boiled for i hr to kill the cells. The killed
cell suspension was centrifuged at 1600 x g for 30 rain, the supernatant
discarded, and the cells resuspended in 2.0 ml of 0.01 M phosphate buffer,
pH 7.2 for each 0.i ml of packed cells. One drop of a I:i000 methiolate
solution was added for each 2.0 ml of preparation. The stock solution
o
was stored at 4 C for i0 days to allow for the release of soluble antigen
from the cells. The suspension was centrifuged at 1600 x g and the super-
natant used for assay development.
Stock Chromogenic Substrate Stain Solution. Two substrates were
utilized for comparison. 0-phenylenediamine (OPD, Abbott Laboratories)
was prepared by dissolving 12.8 mg into 5 ml of citrate phosphate
buffer, pH 7.2, containing 0.02% hydrogen peroxide. 4-chloro-l-napthol
(4ClN, Bio-Rad) was prepared by dissolving 60 mg of 4CIN into 20 ml of
ice cold methanol. Immediately prior to use, 0.06 ml of ice cold 30%
hydrogen peroxide was added to i00 ml of room temperature TBS. The two
solutions were mixed just prior to use.
11-8
METHODS
The ELISA systems for both Bordetella pertussis and Legionella
pneumonphila utilized the Bio-Dot apparatus with the mounted nitro-
cellulose paper. The procedure for assembly of the apparatus and
preparation of the nitrocellulose paper was provided by Bio-Rad
Laboratories (2). Briefly, the nitrocellulose paper was first soaked
in TBS to ensure uniform protein binding and low background absorption.
The cleaned and dried Bio-Dot apparatus was assembled, and the nitro-
cellulose paper sheet wetted prior to being placed in the apparatus.
The apparatus was appropriately tightened to insure that cross well
contamination would not occur.
The flow valve was adjusted to allow the vacuum chamber to be
exposed to the atmosphere and the appropriate wells to receive the
antigen preparation were inoculated with a 0.05 ml volume. (Proteins
bound were minute quantities of either antigen or capture antibody
applied as a 0.05 ml volume of a concentration of 0.1-1.0 mg/ml.)
2
Nitrocellulose paper has a protein binding capacity of 0.08-0.1 mg/cm
The entire sample was allowed to filter through the membrane by gravity
flow (approximtely 30 rain). Each well was filled with the same volume
of sample solution to insure homogeneous filtration of all sample
wells.
After the antigen samples completely drained from the apparatus,
0.2 ml of a 3.0% BSA/TBS blocking solution was applied to each well.
Gravity filtration was allowed to occur until the blocking solution
completely drained from each well (approximately 30 min).
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The flow valve was adjusted to vacuumand 0.4 ml of wash solution
(TBSwith 0.05%tween) was added to each well. The wash solution was
allowed to completely drain from all wells. This process was repeated.
Following the wash step, the flow valve was opened to the atmos-
phere and 0.1 ml of the first antibody solution was added to each of the
wells. The solution was allowed to completely drain from the wells,
and another wash step performed.
With the vaccum off and the flow valve to the atmosphere, 0.1 ml
of second antibody (HPR antibody against the first antibody) was added
to each well. The solution was allowed to completely drain from the
wells.
Following the second antibody step, the vaccum was turned on and
a wash step performed. Immediately, 0.2 ml of a color development
solution, either OPD or 4CIN was applied to each well. A positive ELISA
reaction will be shown as color development depending upon the substate
utilized.
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RESULTS
Non-specific protein binding: A 2.0 cm disc of nitrocellulose
paper was appropriately mounted in a modified millipore apparatus.
The nitrocellulose was washed twice with TBS. A 2.0 ml aliquot of
a BSA solution was allowed to pass through the membrane. A spectro-
photometric reading (320 nm) for protein in the solution was taken
before and after the solution passed through the membrane. The
readings were compared, and it was calculated that the nitrocellulose
2
paper retained approximately 0.ii0 mg/cm of total protein. This was
corrected for the amount of protein released by a wash step.
Enzyme-substrate system: The indicator substrates, OPD and 4CIN,
were tested for their interaction to HPR goat anti-human antibody
•attached to the nitrocellulose paper. Eight rows of 12 cells in the
Bio-Dot apparatus were prepared identically, initially washed with TBS,
followed by the application of 0.05 ml of serial dilutions ranging from
1:100 to 1:10,000 of the HPR goat anti-human serum. Each cell was
blocked against additional protein binding by the coating buffer and
washed with TBS. Different volumes of OPD substrate ranging from 0.05
to 0.3 ml, but consistent for each row was applied to the first four
rows of the cells. Identical volumes were applied to the last four rows
using the 4CIN. Color changes of the substrates were noticable and
complete within 5 rain. Maximum color change of the OPD substrate
occurred with 0.3 ml; however, adequate color change was noticed with
0.2 ml which was subsequently selected for assay development. This
colormetric change allowed visualization of membrane attached antibody
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to a I:i0,000 dilution. Results with the 4ClN were disappointing.
A purple color changewas noted using 0.3 ml of the solution; however,
this occurred with the membraneattached antibody to a 1:300 dilution.
This experiment reflects that i) the nitrocellulose paper was adequately
binding protein (in the form of antibody), 2) the enzyme-substrate
reaction was appropriate, and 3) the OPDappeared to be superior to 4CIN
for ELISA development.
Bordetella pertussis: A humanpool was titrated in the following
manner. Twoduplicate rows of cells were prepared in which 0.05 ml of a
8
I:i0 dilution (approximately 1.8 x i0 organisms/ml) of the Bordetella
pertussis antigen was applied to each well with the exception of the
first two. These wells received 0.05 ml of TBSand served as control
wells for the experiment. All wells then received the blocking buffer
and were rinsed with the wash buffer. A humanpool was serially diluted
from I:i0 to i:i0,000, and 0.i ml of each dilution applied to a subse-
quent well. This step was followed by the addition of 0.i ml of HPR
anti-human serum. Eachwell was then rinsed with the wash buffer. A
0.2 ml aliquot of OPDwas then added to each well. The control wells
showedno color; however, a color changewas evident in the antibody
titration wells out to a 1:1000 dilution.
Titration of pertussis antigen. Twoduplicate rows of cells were pre-
pared in which 0.05 ml of serial dilutions ranging from a 1:10 dilution
8
(containing approximately 1.8 x i0 bacterial cells/ml) to a 1:5,000
5
dilution (containing approximately 3.6 x i0 bacterial cells/ml) with
exception of the first two wells. These wells received 0.05 ml of TBS
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and served as control wells for the experiment. All wells the received
the blocking buffer and were rinsed with the wash buffer. A .i ml
aliquot of a i:i000 dilution of the humanpool was added to each well.
All wells were rinsed with the washbuffer. Eachwell then received
0.i ml of HRPgoat anti-human antibody diluted 1:3000. The wells were
again rinsed with the wash buffer. All wells then received 0.2 ml of
the OPDsolution. Color changeswere evident out to a 1:5000 dilution
5
of the antigen preparation (approximately 1.8 x i0 bacterial cells/ml
4
or 3.6 x i0 bacterial cells/0.05ml). These results are summarized in
Table i.
BordetellaAntigen *McFarland Units Dilution of HumanAntiserum
Dilution Applied i:i0 i:i00 1:1000 1:5000
i:i0 0.02 *,4---_ 2+ i+ 0
1:50 0.001 4+ 3+ i+ 0
i:i00 0.002 4+ 4+ i+ 0
1:500 0.0001 4+ 2+ i+ 0
i:i000 0.0002 3+ 2+ i+ 0
1:5000 0.00001 i+ i+ 0 0
Control 0 0 0 0 0
*i McFarland unit is equivalent to approximately 0.9 x i0
bacterial cells/ml.
**Values are expressed as 0 (as comparable to control) to 4+
for comparison of the color intensity of OPD
Table i. Bordetella pertussis antigen detection.
Legionella pneumophila antigen preparation: The antigen preparation
was subjected to both the Biuret and LOWry protein detection procedures.
The Biuret method showed no detectable protein; however, the results from
the Lowry indicated that the antigen preparation concentration was approx-
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imately .025 mg/ml. Subsequent calculations were determined from this
estimate.
The legionella antigen preparation was titrated in a manner similar
to Bordetella pertussis. Two duplicate rows of cells were prepared in
which 0.05 ml of serial 5 and i0 fold dilutions of the preparation were
applied. The first well of each row served as controls. All wells
received the blocking buffer and were subsequently rinsed with the wash
buffer. This step was followed by the addition of 0.05 ml of a 1:1000
dilution of rabbit legionella antiserum. Each well was then washed and
inoculated with 0.2 ml of the OPD solution.
out to 250 pg/ml of the antigen prepartion.
assay are shown in Table 2.
Color changes were evident
Results from a typical
LegionellaAntigen
Dilution
Protein
Applied
(ng/0.05 ml)
Dilution of legionellaAntiserum
i:i0 1:50 i:i00 i:I000 1:5000
m _ Q
i:i0 25.0 *4+ 4+ 4+ 4+ 3+
1:50 5.0 4+ 4+ 4+ 2+ i+
i:i00 2.5 3+ 3+ 2+ i+ i+
1:500 0.5 3+ 3+ 2+ I+ i+
i:i000 0.25 3+ 3+ 2+ i+ i+
*Values are expressed as 0 (as comparable to control) to 4+ for
comparison of the color intensity of OPD.
Table 2. Legionella pneumophila antigen detection.
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DISCUSSION
During the past decade, numerousimmunoassayshave gained wide
acceptance as the methods of choice in the diagnosis of a number of
disease states (i0). The ideal considerations of a diagnostic test
include speed, sensitivity, specificity, accuracy, safety, inexpensive
reagents, potential for automation, long reagent shelf life, and broad
applicability. Neither immunofluorescenceor radioimmunoassaymeet
all these criteria. Many techniques have been developed recently for
the inm_nological detection of antigens and/or antibodies. Enzyme
immunoassays such as the ELISAs are among the most popular both in
research (10) and clinical laboratory use for the diagnosis of bacteria,
protozoans, and viruses as indicated in Tables 3, 4, and 5, respec-
tively. In general, these tests are user-friendly, reliable, highly
Chlamydia trachomatis
Chlamydelisa (M.A. Bioproducts)
*Chlamydiazyme (Abbott)
Mycoplasma pneumoniae
Mycoplasmelisa (M.A. Bioproducts)
Neisseria gonorrhea
*Gonozyme (Abbott)
Salmonella sp.
*(Kirkegaard and Perry)
Streptococcus pyogenes
*TestPack (Abbott)
*Ventrescreen (Ventrex)
*Quest (Quidel Q)
*ICON (Hybritech)
Table 3. Commercially Available Enzyme-Linked ImmunosorbentAssays
for Bacteria. Asterick (*) denotes antigen detection.
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sensitive and specific, and require little time to run. Addition
considerations include that no power source or instruments are required
for the performance of the tests, little equipment is required, and the
reagents used are stable. Positive reactions are contrasted by out-
standing color changes.
Toxoplasma gondii
Toxoelisa (M.A. Bioproducts)
Toxo-G (Abbott)
Toxo-M (Abbott)
Toxostat (M.A. Bioproducts)
Table 4. Commercially Available Enzyme-Linked Immunosorbent Assays for
Protozoans.
The majority of these commercially available ELISA systems are
designed to detect antibody levels in blood plasma or other biological
fluids (i.e. urine) and few have been developed for the detection of
microbial antigens. The Rotazyme (Abbott) and Pathfinder (Kallestad)
kits which detect the presence of rotaviruses in stool specimens
(Table 5); the Chlamydiazyme (Abbott), Gonozyme (Abbott), Salmonella
detection kit (Kirkegaard and Perry), as well as the Test Pack
(Abbott), Ventrescreen (Ventrex), Quest (Quidel Q), and Icon (Hybritech)
for detection of Streptococcus pyogenes in throat swabs are designed
for antigen detection. It appears advantageous to utilize ELISA
systems directed to detect microbial antigens, particularly for the
demonstration of their presence in certain body regions, biological
fluids, or the external environment.
The commercially available ELISA systems were not designed to be
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CYTOMEGALOVIRUS
Cytomegalisa (M.A. Bioproducts)
CMV-Stat (M.A. Bioproducts)
Cytomegelisa M (Abbott)
CMVtotal AB (Abbott)
HTLVIII
(Abbott)
(Electro-Nucleonics)
(Ortho)
HEPATITI S-A ANTIGEN
Havab (Abbott)
Havab-M (Abbott)
HEPATITIS-BANTIGEN
Ausab (Abbott)
Auszyme II (Abbott)
Corzyme (Abbott)
Corzyme-M (Abbott)
(Ortho)
HEPATATIS-Be ANTIGEN
HBe (Abbott)
HEPATATIS-DELTAANTIGEN
Anti-Delta (Abbott)
HERPES SIMPLEX
Herpelisa 1 (M.A. Bioproducts)
Herpelisa 2 (M.A. Bioproducts)
MUMPS
Mump lisa (M.A. Bioproducts)
ROTAVIRUS
*Rotazyme (Abbott)
*Pathfinder (Kallestad)
RUBELLA
Rubazyme (Abbott)
Rubazyme-M (Abbott)
Rubelisa (M.A. Bioproducts)
Rubelisa-M (M.A. Bioproducts)
Rubestat (M.A. Bioproducts)
RUBEOLA
Measelisa (M.A. Bioproducts)
VARICELLA
Varicelisa (M.A. Bioproducts)
Table 5. Commercially Available Enzyme-Linked Immunosorbent Assays for
Viruses. Asterick (*) denotes antigen detection.
utilized in microgravity, and thus, little concern was given to HMF
requirements during their development. However, the Test Pack (Abbott)
released in June, 1986 for purchase, has been tested in the NASA-JSC
laboratory, and its technology appears to be promising for space station
use. This system is solid phase utilizing an antigen capture filter
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support, in which fluids are contained through diffusion into an
internal absorptive sponge. The system requires approximately i0
minutes to run. The basic flow through system was successfully utilized
in zero gravity experiments aboard the KC135.
The most commonsolid phase supports employed in ELISA systems have
been polystyrene microtiter plates (16) and tubes (13) to which either
antigen or antibody is passively adsorbed, although other supports such
as polystyrene beads (8), sticks (3), and cuvettes (ii) have been
utilized. Antibodies and antigens have also been passively adsorbed to
a numberof other supports including polyvinyl (16), polycarbonate (14),
aminoalkylsilyl glass (7), and silicone rubber ( 5). Covalent coupling
of antigen or antibody to solid phase supports has been successful using
cellulose (15), isothiocynate (4), and polyacrylamide (15). Nitro-
cellulose filter paper, used extensively in the development of DNA probe
technology due to its ability to bind nucleic acids (i), has been found
to nonspecifically bind proteins and has recently been employed as the
binding surface on which immunoassays, such as the ELISA, are performed
(9).
Results from the experiments conducted in this project and the
exsistence of a commercial kit paralleling these findings, provide
a current technology to be considered for the HMF. A major advantage
to consider with the solid phase filter membrane systems is that the
fluids involved in the system can be retained (i.e. little chance of
spillage in the space craft environment). The use of solid phase filter
supports will be soon expanding and kits will eventually be available
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for the identification of those microrganisms, including viruses,
expected to cause health problems in the space station environment.
Since cell culture is usually required for the identification of
viruses, this technology would certainly be an viable alternative.
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